We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Warns Daiichi Sankyo for Misleading Drug Marketing
FDA Warns Daiichi Sankyo for Misleading Drug Marketing
January 26, 2007
The FDA warned Daiichi Sankyo for promotional items it said were misleading because they obscured risk information for Evoxac, a drug that treats dry mouth in patients with Sjogren’s syndrome.